Eli Lilly stock jumped 5% during Tuesday morning trading to about $773 a share after the pharma giant reported ...

Drugmaker Eli Lilly's stock jumped Tuesday as weight loss drugs Mounjaro and Zepbound continue to boost revenue and profits.

(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment ...

"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's ...

Eli Lilly (NYSE:LLY) shares rose ~7% premarket Tuesday after the company increased its full-year outlook above consensus, ...

Just after Eli Lilly posted those numbers, Robyn Karnauskas of Truist Securities revised her fair value estimation of its ...

Eli Lilly & Co.’s shares soared as its brighter outlook for 2024 raised the potential ceiling for new weight-loss drugs even ...

Lilly recently announced news that could solve a big problem.

Eli Lilly noted that tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults that have both obstructive ...

The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s ...

The next frontier for pharma in the obesity space is improving the quality of weight loss. | The next frontier for pharma in ...

Palatin Technologies (PTN) stock gains as the FDA clears a study to test its obesity therapy bremelanotide, with Eli Lillys ...